drugset / Trial / NCT07710768

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

NCT07710768

Phase 1 Not yet recruiting 44 enrolled Novo Nordisk A/S
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.

Timeline

Start
2026-07-15
Primary completion
2027-04-07
Completion
2027-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule Oral
Subject Midazolam Small molecule Oral
Subject UBT251 Unknown Subcutaneous
Subject Warfarin Small molecule Oral

Indications